Better Cancer Diagnostic and Prognostic Testing
for Better Outcomes
Founded in 2022 by Dr. Richard Pestell, StromaGenesis, LLC is a clinical-stage biotechnology company that focuses on tumor microenvironment biology, combining diagnostic precision with therapeutic potential.
Leveraging assets that are the product of over 18 years of academic work to develop:
Proprietary algorithm for a more precise prostate cancer prognosis
Tissue-based immunoassay to predict therapy response in multiple solid tumors (breast, colon, prostate, glioblastoma, etc.), and;
Tissue-based and blood-based immunoassay as companion diagnostic test for multiple solid tumors
Richard Pestell
AO., MD., PhD, MBA, Founder & CEO
Relevant start-up experience: founded/funded ProstaGene, LightSeed, EcoGenome (and sold ProstaGene, 2018)
Inventor of 30 Patents
Director of two NCI Cancer Centers (2002-2016)
Director Lombardi Comprehensive Cancer Center
Georgetown University
Director Sidney Kimmel Comprehensive Cancer Center
Thomas Jefferson University
Oversaw > 120 clinical trials (phase 1, 2, 3)
Established Phase 1 program
Current examiner of NCI designated Cancer Centers
Chairman, Department of Oncology, Georgetown University (2002)
Executive Vice President Thomas Jefferson University (2014)
Annual budget of $5.6B, eleven hospitals | 30,000 employees
World Ranked Oncology Research
Google Scholar (#1 cell cycle, #5 prostate, #13 breast cancer)
600 papers, > 110,000 citations, H index 162
Advisor | Reviewer for NCI Cancer Centers | MD Anderson Breast Cancer
StromaGenesis Team
Stephen Hull
Reimbursement Consultant
Principal at Covance, Sr. Vice President for Global Reimbursement at AdvaMed, President and Founder of Hull Associates LLC, (global reimbursement strategy firm focused on pharmaceutical, medical device, diagnostic and biotech technologies) (Boston, MA) now Avania
Dr. Alberto Guitirez
Regulatory Consultant
Director Office of In Vitro Diagnostics and Radiological Health Director Office of In Vitro Diagnostics and Radiological Health (OVID). FDA 1992 - Sep 2017
Kevin Ellison
Consultant
Almac Group Consultant
ProstaGene™ development
Dr. Hallgeir Rui MD, PhD
Consultant
CLIA Lab Cav1 and CCR5
test development
Andrew Kossenkov
Bioinformatics Consultant
Professor, International leader in Bioinformatics, familiar with Algorithm
Professor X. Jiao
Consultant
Pestell Lab., > 20 years of R&D experience
Professor Z. Li
Consultant
Pestell Lab., > 20 years of R&D experience
StromaGenesis Advisory Board
Recognized Industry Leaders
Dr. Fernando Rubio, PhD
Chief Executive Officer, Eurofins Abraxis L.L.C. | https://www.eurofins.com/contact-us/worldwide-interactive-map/usa/eurofins-abraxis/
Founder Abraxis, Clinical diagnostics (genetics), manufacturing and distribution company. >110 million tests per year
Eurofins clinical diagnostics laboratories offer testing services in all medical specialties, from routine testing to esoteric testing including advanced and often proprietary genetic testing solutions. (now Gold Standards Diagnostic
Dr. Thomas Errico, MD
Founder K2M Group Holdings, Inc, in 2004, (>$280 million in annual revenue, sold $1.4 billion)
Founder, Board member of Electrocore
Dr. Denis Burger, PhD
Developed and brought 4 companies to NASDAQ
Trinity Biotech Co-founder and Chairman
Previous Vice Chairman of CytoDyn Inc. Chairman and Chief Executive Officer of AVI Biopharma Inc, non-executive director of Aptose Biosciences, Inc, a cancer therapeutics, TSX and NASDAQ listed company, and co-founder and Chairman of Epitope Inc
Dr. Hallgeir Rui, MD, PhD
Professor of Pharmacology & Cancer Biology, Thomas Jefferson University
Director, Translational Pathology Core, Sidney Kimmel Cancer Center
100 East Lancaster Ave
Room R234
Wynnewood, Pennsylvania 19096
General inquiries:
© 2025 StromaGenesis. All rights reserved.
Privacy Policy